Soligenix Inc
SNGX
Market Cap$6.07M
Close$
$3.69
87.4% upside
Current Fair Value
87.4% upsideUndervalued by 87.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.07 Million |
|---|---|
| Enterprise Value | $-263,405.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.23 |
| Beta | 1.86 |
| Outstanding Shares | 2,203,929 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.51 |
|---|---|
| PEG | -15.05 |
| Price to Sales | - |
| Price to Book Ratio | 1.97 |
| Enterprise Value to Revenue | -0.72 |
| Enterprise Value to EBIT | 0.03 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -5.64 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Soligenix Inc
18 employees
CEO: Christopher Schaber Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.